A closer look at industry issues

 

As we announced several weeks ago, FiercePharma will be featuring a new special section called Industry Voices. A variety of columnists will discuss issues affecting the pharmaceutical industry and examine the trends that are changing the way drug makers do business. We hope this feature will give you deeper insight into larger issues that don't always make the daily news cycle.

Our first columnist is Mark Senak, an industry expert with over twenty years of experience in law, communications, public health and public relations. He is also the author of Eye on FDA, a popular blog covering the ins and outs of FDA news and policy. Scroll down to check out his article on the recent upheaval at the FDA, or click here to read it online. - Maureen

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

Pfizer terminated a slew of trial cohorts testing Bavencio in combination with its own experimental drugs, as well as one monotherapy trial.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.